请输入您要查询的百科知识：

　

词条 Multiple sclerosis research
释义

  1. Research directions

     Treatments  Etiology and pathogenesis  Imaging  Personalized medicine  Biomarkers  Types 

  2. Clinical measures of evolution

     NEDA 

  3. Research into pathogenesis

     Geographical Causes  Genetics  Heterogeneity  GDP-L-fucose synthase  Progressive variants 

  4. Disease-modifying drugs

     Relapsing-remitting MS  Secondary progressive variants  Treatment for Primary Progressive variants  Highly active relapsing remitting variant 

  5. References

Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.

Research directions

Research directions on MS treatments include investigations of MS pathogenesis and heterogeneity; research of more effective, convenient, or tolerable new treatments for RRMS; creation of therapies for the progressive subtypes; neuroprotection strategies; and the search for effective symptomatic treatments.[1]

Treatments

Advancements during the last decades have led to the recent approval of several oral drugs. These drugs are expected to gain in popularity and frequency of use at the expense of previously existing therapies.[2] Further oral drugs are still under investigation, the most notable example being laquinimod, which was announced in August 2012 to be the focus of a third phase III trial after mixed results in the previous ones.[3] Early trials of the female sex hormone estriol, led in part by Rhonda Voskuhl, have generated interest in reducing symptoms in women with RRMS.[4][5][6] Similarly, several other studies are aimed to improve efficacy and ease of use of already existing therapies through the use of novel preparations.[7] Such is the case the PEGylated version of interferon-β-1a, that has a longer life than normal interferon and therefore it is being studied if given at less frequent doses has a similar efficacy than the existing product.[8][9] Request for approval of peginterferon beta-1a is expected during 2013.[9]

Monoclonal antibodies, which are biological drugs of the same family as natalizumab, have also raised high levels of interest and research. Alemtuzumab, daclizumab and CD20 monoclonal antibodies such as rituximab, ocrelizumab and ofatumumab have all shown some benefit and are under study as potential treatments for MS.[10] Nevertheless, their use has also been accompanied by the appearance of potentially dangerous adverse effects, most importantly opportunistic infections.[2] Related to these investigations is the recent development of a test against JC virus antibodies which might help to predict what patients are at a greater risk of developing progressive multifocal leukoencephalopathy when taking natalizumab.[2] While monoclonal antibodies are probably going to have some role in the treatment of the disease in the future, it is believed that it will be small due to the risks associated to them.[2][11]

Another research strategy is to evaluate the combined effectiveness of two or more drugs.[12] The main rationale for polytherapy in MS is that the involved treatments target different mechanisms of the disease and therefore, their use is not necessarily exclusive.[12] Moreover, synergies, in which a drug potentiates the effect of another are also possible. Nevertheless, there can also appear important drawbacks such as antagonizing mechanisms of action or potentiation of deleterious secondary effects.[12] While there have been several clinical trials of combined therapy none has shown positive enough effects to merit the consideration as a viable treatment for MS.[12]

Regarding neuroprotective and regenerative treatments such as stem cell therapy, while their research is considered of high importance at the moment they are only a promise of future therapeutic approaches.[13] Likewise, there are not any effective treatments for the progressive variants of the disease. Many of the newest drugs as well as those under development are probably going to be evaluated as therapies for PPMS or SPMS, and their improved effectiveness when compared with previously existing drugs may eventually lead to a positive result in these groups of patients.[2]

Etiology and pathogenesis

There are several ways of research open about the cause of MS, ranging from metabolic disregulations to external infections.

Regarding the possibility of external infections, there are recent news about anti-CD20 monoclonal antibodies against EBV B-cells which are considered by some people as an important clue over pathogenesis[14]

There are also some reports considering that current diagnostic methods are confusing several disease entities into the same clinical entity "multiple sclerosis". For example, neuromyelitis optica, formerly considered a kind of MS, was separated in 2006 with the discovery of AQP4-IgG, and currently a second variant has been separated, antiMOG associated encephalomyelitis. Some other conditions are expected to be distinguished from MS following the discovery of specific pathogens.[15]

Imaging

While MRI is used normally for diagnosis and follow up, it has limitations. New MRI technologies like pulse sequences and post-processing are under study.

Anyway some of the features of MS, like microglia activation, are invisible to MRI. Therefore positron emission tomography (PET) is preferred in the current studies[16]

Personalized medicine

Personalized medicine refers to the expected possibility of classifying patients as good or bad responders before starting a therapy. Given the side effects of all MS medications, this is currently an active field of research.[17]

About this, in 2013 appeared reports of a new kind of multiple sclerosis without white matter demyelination that affects 12% of the patients and could behave differently from the rest of patients[18] Later its existence was confirmed (2018)[19]

Biomarkers

Main:Multiple sclerosis biomarkers

Several biomarkers for diagnosis, disease evolution and response to medication (current or expected) are under research. While most of them are still under research, there are some of them already well stablished:

  • oligoclonal bands: They present proteins that are in the CNS or in blood. Those that are in CNS but not in blood suggest a diagnosis of MS.
  • MRZ-Reaction: A polyspecific antiviral immune response against the viruses of measles, rubella and zoster found in 1992.[20] In some reports the MRZR showed a lower sensitivity than OCB (70% vs. 100%), but a higher specificity (69% vs. 92%) for MS.[20]
  • free light chains (FLC). Several authors have reported that they are comparable or even better than oligoclonal bands.[21]

Types

Some reports critic the current division on MS in "types". Specially they point that the "types" were artificially made up, just to treat RRMS as a separate disease. In this way the number of patients was low enough to get the interferon approved by the FDA under the orphan drugs act.[22]

Clinical measures of evolution

Currently it is accepted that the standard course of the disease presents three different clinical stages. A preclinical or prodromal stage, also termed RIS (radiologically isolated sindrome), a relapsing stage and finally a progressive stage.[23]

The main measure of evolution of symptoms, specially important as an endpoint in MS trials, is the EDSS (extended dissability status score). However, this and other measures used in clinical studies are far from perfect and suffer from insensitivity or inadequate validation.[24] In this sense there is ongoing research to improve the EDSS and other measures such as the multiple sclerosis functional composite. This is important as the greater efficacy of existing medications force functional measures in clinical trials to be highly sensitive in order to adequately measure disease changes.[24]

NEDA

Currently the criteria for testing the evolution is moving from raw EDSS (dissability status) to NEDA (No evidence of disease activity). Several NEDA criteria have been published. NEDA-3 means that EDSS remains constant, MRI shows no activity and no relapses have appeared. NEDA-4 means NEDA-3 plus that brain atrophy has not increased. Some authors speak about a NEDA-3+ which is a NEDA-3 plus no cortical lesions.[25]

Research into pathogenesis

Research into pathogenesis focuses on explaining the ultimate causes of MS onset and progression, and explaining the heterogeneous behaviour[1]

Pathological research tries to obtain correlations for the observable biomarkers. Several important areas of study have been delimited, like Normal Appearing White Matter areas, which are the source of the lesions and under special MRI techniques like Magnetic Resonance Spectroscopy have been found to have a similar molecular composition.[26]

Also some external agents can modify the disease course. Smoking is known to modify (for worse) the course of the disease, and recently this effect has been seen via MRI.[27] An explanation of this effect could shed some light into the pathogenesis.

Geographical Causes

Extensive research on multiple sclerosis is being done on what parts of the world have higher rates of MS compared to other regions. Researchers have studied MS mortality statistics in various latitudes of the earth and the pattern shows that MS mortality rates are lowest in equatorial regions, which contain the countries, Ethiopia and Jamaica. It increases towards the north and south showing that the highest MS rate is at a latitude of around 60 degrees, which are the countries Orkney, Shetland Islands, and Oslo, Norway. The next step for researchers would be to consider what factors are different at the latitudes of 60 degrees and the equatorial regions and continue to narrow down their theories for the exact cause of MS.

[28]

Genetics

Advances in genetic testing techniques have led to a greater understanding of the genetics of MS. However, it is hard to predict how these future discoveries will impact clinical practice or research for new drugs and treatments.[2]

An example of a soon-to-be finished study is the Wellcome Trust case control consortium, a collaboration study including 120,000 genetic samples, of which 8000 are from individuals with MS.[29] This study may presumably identify all the common genetic variants involved in MS.[29] Further studies will probably involve full genome sequencing of large samples, or the study of structural genetic variants such as insertions, deletions or polymorphisms.[29]

Genetic factors are the primary cause to the more rapid progression and frequency of the disease. Although genetics is linked to multiple sclerosis, most of the prime perceptivity of the linkage has not been fully characterized as there has not been a big enough sample size available for the research needed.[30] Some genetic mutations have been associated with an increased risk to develop MS, like STK11-SNP.[31] The chronic demyelination may cause axons to be notably vulnerable to repetitive and increasing injury and destruction.[32]

Heterogeneity

MS is a clinically defined entity with several atypical presentations. Some auto-antibodies have been found in atypical MS cases, giving birth to separate disease families and restricting the previously wider concept of MS.

First of all, anti-AQP4 autoantibodies were found in neuromyelitis optica (NMO), which was previously considered a MS variant. After that, a whole spectrum of diseases named NMOSD (NMO spectrum diseases) or anti-AQP4 diseases has been accepted.[33]

Later, it was found that some cases of MS were presenting anti-MOG autoantibodies, mainly overlapping with the Marburg variant. Anti-MOG autoantibodies were found to be also present in ADEM, and now a second spectrum of separated diseases is being considered. At this moment, it is named inconsistently across different authors, but it is normally something similar to anti-MOG demyelinating diseases.[33]

Finally, a third kind of auto-antibodies is accepted. They are several anti-neurofascin auto-antibodies which damage the Ranvier nodes of the neurones. These antibodies are more related to the peripheral nervous demyelination, but they were also found in chronic progressive PPMS and combined central and peripheral demyelination (CCPD, which is considered another atypical MS presentation).[34]

Besides all this autoantibodies found, four different patterns of demyelination have been reported in MS, opening the door to consider MS as an heterogeneous disease.[35]

GDP-L-fucose synthase

GDP-L-fucose synthase is the only autoantigen reported to date in a subset of MS patients[36][37] It is currently unknown if it is pathogenic or a side effect of the disease.

Progressive variants

Cortical atrophy and demyelination along the subpial surface appear early in the disease course but accelerate in progressive stage. Inflammatory infiltrates appear in the meninges, in some cases with B cell follicles. Leptomeningeal enhancement under MRI is common in patients with progressive forms of MS and shows a relationship to subpial cortical lesions and cortical atrophy.[38]

Disease-modifying drugs

{{main|Multiple sclerosis drug pipeline}}

Disease-modifying drugs represent possible interventions able to modify the natural course of the disease instead of targeting the symptoms or the recovery from relapses.[39] Over a dozen clinical trials testing potential therapies are underway, and additional new treatments are being devised and tested in animal models.

New drugs must pass several clinical trials in order to get approved by regulatory agencies. Phase III is normally the last testing phase and when results are as expected a formal approval request is submitted to the regulator. Phase III programs consist of studies on large patient groups (300 to 3,000 or more) and are aimed at being the definitive assessment of how effective and safe a test drug will be. It is the last stage of drug development and is followed by a submission to the appropriate regulatory agencies (e.g., European Medicines Agency (EMEA) for the European Union, the Food and Drug Administration (FDA) for the United States, Therapeutic Goods Administration (TGA) for Australia, etc.) to obtain approval for marketing. Treatment in MS phase III studies is usually 2 years per patient.

Relapsing-remitting MS

Currently there are several ongoing phase III trials, and there are also some drugs that are waiting for approval after finishing theirs.

For example, Cladribine (under development by Merck Serono; anticipated brand name: Movectro) is a antineoplastic oral drug with immunosuppressive effects. It is already currently used as an intravenous infusion to treat hairy cell leukemia (leukemic reticuloendotheliosis). An oral version of cladribine is in phase III.[40] The completion of the phase III program took place in early 2009 meeting its main endpoint with 58% relative reduction in annualized relapse rates with respect to placebo.[41] Formal submission to European EMEA took place in middle 2009. In January 2010, researchers published in NEJM significant results of cladribine use in reducing relapsing course of multiple sclerosis.[42] This drug was expected to be in the market in 2011 for use in multiple sclerosis patients.,[43][44] but in 2011 the company decided to stop selling the tablets in Russia and Australia though it was already approved in this countries.[45] Nevertheless, it seems that approval process continued in Europe and the EMEA has accepted a review process[46]

The following drugs, at least, are also in phase III (for a complete list see Multiple sclerosis drug pipeline):

  • Tovaxin (injectable) A vaccine against self T-Cells, which consist of attenuated autoreactive T cells. It is developed by Opexa Therapeutics, (previously known as PharmaFrontiers), and finished a phase IIb September 2008,[47] failing its primary target though in March 2008 was still performing good.[48] After several financial troubles, a phase III trial has been granted in 2011[49]
  • Siponimod, (BAF312) is a sphingosine-1-phosphate receptor modulator for oral use for MS. A phase III trial should run from Dec 2012 to Dec 2016.[50]

Secondary progressive variants

Relapsing-Onset variants (RO), even when they turn into progressive, have proved easier to treat than Progressive-Onset variants. Though difficult to treat, Secondary progressive and Progressive-Relapsing are easier to treat than PPMS. Only Mitoxantrone has been approved for them, but there is nothing for PPMS. At this moment several therapies are under research:

  • Cyclophosphamide (trade name Revimmune) is currently in Phase III for secondary progressive MS.[51] It was also studied for RRMS but the company does not pursue actively this path. After a 2006 study for refractory cases it showed good behaviour[52] Later, a 2007 open label study found it equivalent to Mitoxantrone[53] and in 2008 evidence appeared that it can reverse disability.[54]
  • Simvastatin has shown brain atrophy reduction in secondary progressive MS.[55]
  • Tcelna is currently under active research by Opexa, showing promising results.[56]
  • Masitinib, a tyrosine kinase inhibitor, is in late-stage testing for the treatment of patients with secondary and primary progressive MS (PPMS). It is a twice-daily oral medication that targets mast cells and inhibits several biochemical processes.14
  • Ibudilast: MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for "fast track" development by the U.S. Food and Drug Administration (FDA) as of 2016, as a potential treatment for progressive multiple sclerosis (MS). Progressive MS in this case means both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease.

Treatment for Primary Progressive variants

Most Progressive-Onset variants does not have any approved disease-modifying treatment currently. Some possible treatments have been published, such as methylprednisolone pulses[57] or riluzole,[58] and some reduction of spasticity was reported in a pilot Italian study on low dose naltrexone[59] but there is nothing conclusive still.

Currently, good results using the monoclonal antibody Ocrelizumab in primary progressive MS (PPMS)[60] have put the focus into depleting B cells targeting CD20 proteins[61]

A Statin, Simvastatin (Zocor), has shown good results in progressive variants[62] Also Masitinib and Ibudilast, mainly targeted to SPMS have recruited PPMS patients in their clinical trials with good results.

Respect the etiological research, a special genetic variant named rapidly progressive multiple sclerosis[63] has been described. It is due to a mutation inside the gene NR1H3, an arginine to glutamine mutation in the position p.Arg415Gln, in an area that codifies the protein LXRA.

Highly active relapsing remitting variant

Highly Active Relapsing Remitting, sometimes called Rapidly Worsening relapsing remitting, is a clinical form considered distinct from standard RRMS during clinical trials, being normally non responsive to standard medication.

As of 2011, fingolimod has been approved as the first disease modifying therapy for this clinical course.[64] Cyclophosphamide is currently used off-label for Rapidly Worsening MS (RWMS).[65]

References

1. ^1 {{cite journal |author=Cohen JA |title=Emerging therapies for relapsing multiple sclerosis |journal=Arch. Neurol. |volume=66 |issue=7 |pages=821–8 |date=July 2009 |pmid=19597083 |doi=10.1001/archneurol.2009.104 |url=}}
2. ^1 2 3 4 5 {{cite journal |author=Miller AE |title=Multiple sclerosis: where will we be in 2020? |journal=Mt. Sinai J. Med. |volume=78 |issue=2 |pages=268–79 |year=2011 |pmid=21425270 |doi=10.1002/msj.20242 |url=}}
3. ^{{cite news|last=Jeffrey|first=susan|title=CONCERTO: A Third Phase 3 Trial for Laquinimod in MS|url=http://www.medscape.com/viewarticle/768902|accessdate=21 May 2013|newspaper=Medscape Medical News|date=9 Aug 2012}}
4. ^{{Cite journal|last=Sicotte|first=Nancy L.|last2=Liva|first2=Stephanie M.|last3=Klutch|first3=Rochelle|last4=Pfeiffer|first4=Paul|last5=Bouvier|first5=Seth|last6=Odesa|first6=Sylvia|last7=Wu|first7=T. C. Jackson|last8=Voskuhl|first8=Rhonda R.|date=2002-10-01|title=Treatment of multiple sclerosis with the pregnancy hormone estriol|journal=Annals of Neurology|language=en|volume=52|issue=4|pages=421–428|doi=10.1002/ana.10301|pmid=12325070|issn=1531-8249}}
5. ^{{Cite journal|last=Gold|first=Stefan M.|last2=Voskuhl|first2=Rhonda R.|title=Estrogen treatment in multiple sclerosis|journal=Journal of the Neurological Sciences|volume=286|issue=1–2|pages=99–103|doi=10.1016/j.jns.2009.05.028|pmid=19539954|pmc=2760629|year=2009}}
6. ^{{Cite journal|last=Voskuhl|first=Rhonda R|last2=Wang|first2=HeJing|last3=Wu|first3=T C Jackson|last4=Sicotte|first4=Nancy L|last5=Nakamura|first5=Kunio|last6=Kurth|first6=Florian|last7=Itoh|first7=Noriko|last8=Bardens|first8=Jenny|last9=Bernard|first9=Jacqueline T|title=Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial|journal=The Lancet Neurology|volume=15|issue=1|pages=35–46|doi=10.1016/s1474-4422(15)00322-1|pmid=26621682|year=2016|url=http://www.escholarship.org/uc/item/8zz3v374}}
7. ^{{cite journal | last=Mendoza |first=RL | year = 2014 | title = Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union | journal = Journal of Public Health | volume = 22 | issue = 3| pages = 211–218 | doi=10.1007/s10389-013-0561-z}}
8. ^{{cite journal |last1=Kieseier |first1=BC |last2=Calabresi |first2=PA |title=PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis |journal=CNS Drugs |volume=26 |issue=3 |pages=205–14 |date=March 2012 |pmid=22201341 |doi=10.2165/11596970-000000000-00000 |url=}}
9. ^1 {{cite press release|url=http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1777510|title=Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis|publisher=Biogen Idec|date=2013-01-24|accessdate=2013-05-21|deadurl=yes|archiveurl=https://web.archive.org/web/20131004220459/http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1777510|archivedate=2013-10-04|df=}}
10. ^{{cite journal |vauthors=Saidha S, Eckstein C, Calabresi PA |title=New and emerging disease modifying therapies for multiple sclerosis |journal=Annals of the New York Academy of Sciences |volume=1247 |issue= 1|pages=117–37 |date=January 2012 |pmid=22224673 |doi=10.1111/j.1749-6632.2011.06272.x |url=|bibcode=2012NYASA1247..117S }}
11. ^{{Cite journal |last=Kappos |first=Ludwig |last2=Wiendl |first2=Heinz |author-link2=Heinz Wiendl |last3=Selmaj |first3=Krzysztof |last4=Arnold |first4=Douglas L. |last5=Havrdova |first5=Eva |last6=Boyko |first6=Alexey |last7=Kaufman |first7=Michael |last8=Rose |first8=John |last9=Greenberg |first9=Steven |year=2015 |title=Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis |journal=New England Journal of Medicine |volume=373 |issue=15 |pages=1418–1428 |doi=10.1056/nejmoa1501481 |pmid=26444729 |last10=Sweetser |first10=Marianne |last11=Riester |first11=Katherine |last12=o'Neill |first12=Gilmore |last13=Elkins |first13=Jacob}}
12. ^1 2 3 {{cite journal |vauthors=Milo R, Panitch H |title=Combination therapy in multiple sclerosis |journal=J. Neuroimmunol. |volume=231 |issue=1–2 |pages=23–31 |date=February 2011 |pmid=21111490 |doi=10.1016/j.jneuroim.2010.10.021 |url=}}
13. ^{{cite journal |vauthors=Luessi F, Siffrin V, Zipp F |title=Neurodegeneration in multiple sclerosis: novel treatment strategies |journal=Expert Rev Neurother |volume=12 |issue=9 |pages=1061–76; quiz 1077 |date=September 2012 |pmid=23039386 |doi=10.1586/ern.12.59 }}
14. ^{{cite journal |author=Michael P Pender |author2=Scott R Burrows |title=Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy |journal=Clin Trans Immunol |volume=3 |issue= 10|pages=e27 |date=31 October 2014 |doi=10.1038/cti.2014.25|pmid=25505955 |pmc=4237030 }}
15. ^{{cite journal |author=Ichiro Nakashima |title=Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases |journal=Neuroimmunology |volume=6 |issue=S1 |pages=59–63 |date=December 2015 |doi=10.1111/cen3.12262}}
16. ^{{cite journal | vauthors=Laura A, Eero R, Juha OR|title=Imaging neuroinflammation in multiple sclerosis using TSPO-PET |journal=Clinical and Translational Imaging |volume=3 |issue=6 |pages=461–473 |date=December 2015 |doi=10.1007/s40336-015-0147-6|pmid=27331049 |pmc=4887541 }}
17. ^{{Cite journal |doi = 10.1038/nrneurol.2015.200|pmid = 26503926|title = New drugs and personalized medicine for multiple sclerosis|journal = Nature Reviews Neurology|volume = 11|issue = 11|pages = 614–616|year = 2015|last1 = Matthews|first1 = Paul M.}}
18. ^{{Cite journal |last=Hendrickson |first=Megan |title=Myelocortical multiple sclerosis: a subgroup of multiple sclerosis patients with spinal cord and cortical demyelination |url=http://onlinelibrary.ectrims-congress.eu/ectrims/2013/copenhagen/34294/megan.hendrickson.myelocortical.multiple.sclerosis.a.subgroup.of.multiple.html}}
19. ^{{Cite journal |doi = 10.1016/S1474-4422(18)30245-X|pmid = 30143361|pmc = 6197820|title = Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: A retrospective study|journal = The Lancet Neurology|volume = 17|issue = 10|pages = 870–884|year = 2018|last1 = Trapp|first1 = Bruce D.|last2 = Vignos|first2 = Megan|last3 = Dudman|first3 = Jessica|last4 = Chang|first4 = Ansi|last5 = Fisher|first5 = Elizabeth|last6 = Staugaitis|first6 = Susan M.|last7 = Battapady|first7 = Harsha|last8 = Mork|first8 = Sverre|last9 = Ontaneda|first9 = Daniel|last10 = Jones|first10 = Stephen E.|last11 = Fox|first11 = Robert J.|last12 = Chen|first12 = Jacqueline|last13 = Nakamura|first13 = Kunio|last14 = Rudick|first14 = Richard A.}}
20. ^1 {{Cite journal |doi=10.1186/s12987-015-0024-8 |pmc=4677451 |pmid=26652013|year=2015 |last1=Hottenrott |first1=T. |title=The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort |journal=Fluids and Barriers of the CNS |volume=12 |pages=27 |last2=Dersch |first2=R. |last3=Berger |first3=B. |last4=Rauer |first4=S. |last5=Eckenweiler |first5=M. |last6=Huzly |first6=D. |last7=Stich |first7=O. }}
21. ^{{Cite journal |last=Duranti |first=Fabio |last2=Pieri |first2=Massimo |last3=Zenobi |first3=Rossella |last4=Centonze |first4=Diego |last5=Buttari |first5=Fabio |last6=Bernardini |first6=Sergio |last7=Dessi |first7=Mariarita |title=kFLC Index: a novel approach in early diagnosis of Multiple Sclerosis |url=http://worldwidejournals.in/ojs/index.php/ijsr/article/download/6571/6613 |journal=International Journal of Scientific Research |volume=4 |issue=8}}
22. ^R. Dobson G. Giovannoni, Multiple sclerosis – a review, 09 October 2018, https://doi.org/10.1111/ene.13819
23. ^{{Cite journal |date=Feb 2018 |title=Multiple Sclerosis: Mechanisms and Immunotherapy. |journal=Neuron |volume=97 |issue=4 |pages=742–768 |doi=10.1016/j.neuron.2018.01.021 |pmid=29470968|last1=Baecher-Allan |first1=C. |last2=Kaskow |first2=B. J. |last3=Weiner |first3=H. L. }}
24. ^1 {{cite journal|vauthors=Cohen JA, Reingold SC, Polman CH, Wolinsky JS |author-link4=Jerry Wolinsky|title=Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects |journal=Lancet Neurol |volume=11 |issue=5 |pages=467–76 |date=May 2012|pmid=22516081 |doi=10.1016/S1474-4422(12)70059-5 |url=}}
25. ^{{Cite journal |doi = 10.1177/1756286418805713|pmid = 30386435|pmc = 6204617|title = NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis|journal = Therapeutic Advances in Neurological Disorders|volume = 11|pages = 175628641880571|year = 2018|last1 = Puthenparampil|first1 = Marco|last2 = Cazzola|first2 = Chiara|last3 = Zywicki|first3 = Sofia|last4 = Federle|first4 = Lisa|last5 = Stropparo|first5 = Erica|last6 = Anglani|first6 = Mariagiulia|last7 = Rinaldi|first7 = Francesca|last8 = Perini|first8 = Paola|last9 = Gallo|first9 = Paolo}}
26. ^{{cite journal | author = Fleischer Vinzenz|display-authors=etal| year = 2016 | title = Metabolic Patterns in Chronic MS Lesions and Normal-appearing White Matter: Intraindividual Comparison by Using Two-Dimensional MR Spectroscopic Imaging | url = | journal = Neuroradiology | volume = 281| issue = 2| pages = 536–543| doi = 10.1148/radiol.2016151654 | pmid = 27243371 }}
27. ^{{Cite journal |doi=10.5152/dir.2015.15415 |pmid=27015443|pmc=4859748|year=2016|last1=Durhan|first1=G.|title=Influence of cigarette smoking on white matter in patients with clinically isolated syndrome as detected by diffusion tensor imaging|journal=Diagnostic and Interventional Radiology (Ankara, Turkey)|volume=22|issue=3|pages=291–296|last2=Diker|first2=S.|last3=Has|first3=A. C.|last4=Karakaya|first4=J.|last5=Kurne|first5=A. T.|last6=Oguz|first6=K. K.}}
28. ^{{Cite journal |doi = 10.1111/j.1467-8306.1981.tb01338.x|title = Geographical Clues about Multiple Sclerosis|journal = Annals of the Association of American Geographers|volume = 71|pages = 28–39|date = March 1981|last1 = Mayer|first1 = Jonathan D.}}
29. ^1 2 {{cite journal |author=Baranzini SE |title=Revealing the genetic basis of multiple sclerosis: are we there yet? |journal=Current Opinion in Genetics & Development |volume=21 |issue=3 |pages=317–24 |date=June 2011|pmid=21247752 |pmc=3105160 |doi=10.1016/j.gde.2010.12.006 |url=}}
30. ^{{cite journal |author1=Sawcer S. |author2=Hellenthal G. |author3=Pirinen M. |author4=Spencer C.C.A. |author5=Patsopoulos N. A. |author6=Moutsianas L. | year = 2011 | title = Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | url = | journal = Nature | volume = 476 | issue = 7359| pages = 214–219 | doi = 10.1038/nature10251 |display-authors=etal | pmid=21833088 | pmc=3182531|bibcode=2011Natur.476..214T }}
31. ^{{Cite news | url=https://www.labmedica.com/genetic_testing/articles/294757745/mutation_identified_as_genetic_marker_for_multiple_scle_.html | title=Mutation Identified as Genetic Marker for Multiple Sclerosis| date=2015-03-16}}
32. ^{{cite journal |author1=Frischer J.M. |author2=Bramow S. |author3=Dal-Bianco A. |author4=Lucchinetti C.F. |author5=Rauschka H. | year = 2009 | title = The relation between inflammation and neurodegeneration in multiple sclerosis brains | url = | journal = Brain | volume = 132 | issue = 5| pages = 1175–89 | doi=10.1093/brain/awp070|pmid=19339255 |display-authors=etal|pmc=2677799}}
33. ^1 Tatsuro Misu, Kazuo Fujihara, Neuromyelitis optica spectrum and myelin oligodendrocyte glycoprotein antibody‐related disseminated encephalomyelitis, 30 December 2018, Clin. and Exp. Neuroimmunology, doi: https://doi.org/10.1111/cen3.12491
34. ^Jun-ichi Kira, Ryo Yamasaki, Hidenori Ogata, Anti-neurofascin autoantibody and demyelination, Dec 2018, Neurochemistry International, doi: https://doi.org/10.1016/j.neuint.2018.12.011
35. ^Bogdan F. Gh. Popescu, Istvan Pirko, Claudia F. Lucchinetti, Pathology of Multiple Sclerosis: Where Do We Stand? Continuum (Minneap Minn). 2013 Aug; 19(4 Multiple Sclerosis): 901–921. {{doi|10.1212/01.CON.0000433291.23091.65}}, PMCID: PMC3915566, {{PMID|23917093}}
36. ^{{Cite news |url=http://neurosciencenews.com/multiple-sclerosis-gut-flora-10003/ |title=Link Between Gut Flora and Multiple Sclerosis Discovered |date=2018-10-11 |work=NeuroscienceNews}}
37. ^{{Cite journal |doi=10.1126/scitranslmed.aat4301|pmid=30305453|title=GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis|journal=Science Translational Medicine|volume=10|issue=462|pages=eaat4301|year=2018|last1=Planas|first1=Raquel|last2=Santos|first2=Radleigh|last3=Tomas-Ojer|first3=Paula|last4=Cruciani|first4=Carolina|last5=Lutterotti|first5=Andreas|last6=Faigle|first6=Wolfgang|last7=Schaeren-Wiemers|first7=Nicole|last8=Espejo|first8=Carmen|last9=Eixarch|first9=Herena|last10=Pinilla|first10=Clemencia|last11=Martin|first11=Roland|last12=Sospedra|first12=Mireia|url=https://www.zora.uzh.ch/id/eprint/158835/1/2018_Planas_GDP_L-Fucose_Sci_Transl._Med._in_press.pdf}}
38. ^{{cite journal | author = Zurawski Jonathan, Lassmann Hans, Bakshi Rohit | year = 2016 | title = Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review | url = | journal = JAMA Neurol | volume = 74| issue = 1| pages = 100–109| doi = 10.1001/jamaneurol.2016.4237 | pmid = 27893883 }}
39. ^{{cite journal | author = Lee Mendoza R | year = 2014 | title = Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union | journal = Journal of Public Health | volume = 22 | issue = 3| pages = 211–218 | doi=10.1007/s10389-013-0561-z}}
40. ^clinicaltrial.gov CLARITY Study. {{Webarchive|url=https://web.archive.org/web/20110721034459/http://www.clinicaltrial.gov/ct2/show/NCT00213135?term=clarity&rank=3 |date=2011-07-21 }} Retrieved on 25 November 2007.
41. ^{{Cite web |url=http://www.tradingmarkets.com/.site/news/Stock%20News/2146783/ |title=Merck Serono's Phase III multiple sclerosis trial meets endpoint |access-date=2016-07-26 |archive-url=https://web.archive.org/web/20090417174703/http://www.tradingmarkets.com/.site/news/Stock%20News/2146783/ |archive-date=2009-04-17 |dead-url=yes |df= }}
42. ^{{cite journal | doi = 10.1056/NEJMoa0902533 | pmid = 20089960 | title = A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis | journal = New England Journal of Medicine | volume = 362 | issue = 5 | pages = 416–26 | year = 2010 | last1 = Giovannoni | first1 = Gavin | last2 = Comi | first2 = Giancarlo | last3 = Cook | first3 = Stuart | last4 = Rammohan | first4 = Kottil | last5 = Rieckmann | first5 = Peter | last6 = Sørensen | first6 = Per Soelberg | last7 = Vermersch | first7 = Patrick | last8 = Chang | first8 = Peter | last9 = Hamlett | first9 = Anthony | last10 = Musch | first10 = Bruno | last11 = Greenberg | first11 = Steven J. }}
43. ^Merck KGaA Submits Application For Cladribine Tablets As Multiple Sclerosis Therapy In Europe  
44. ^{{Cite news | url=http://news.bbc.co.uk/2/hi/health/8470138.stm | title=Hope for MS pill after cladribine and fingolimod trials| date=2010-01-20}}
45. ^{{Cite web | url=http://www.genengnews.com/gen-news-highlights/merck-serono-gives-up-on-getting-drug-candidate-for-multiple-sclerosis-approved/81245334/ | title=Merck Serono Gives up on Getting Drug Candidate for Multiple Sclerosis Approved| date=2011-06-22}}
46. ^Press release
47. ^[https://www.forbes.com/feeds/ap/2008/09/19/ap5448876.html Opexa shares lose most of value on study data ]
48. ^Opexa Therapeutics Announces Completion Of Mid Study Descriptive Analysis On Phase IIb Trial Of Tovaxin
49. ^Tovaxin phase III announced http://www.opexatherapeutics.com/?page=release§ion=news&article=010511
50. ^[https://clinicaltrials.gov/ct2/show/NCT01665144 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)]
51. ^Significant Advances in Multiple Sclerosis Treatment http://www.pharmacytimes.com/publications/specialty-pt/2011/February-2011/SPT-NPP-0211
52. ^{{cite journal |vauthors=Gladstone DE, Zamkoff KW, Krupp L, etal |title=High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis |journal=Arch. Neurol. |volume=63 |issue=10 |pages=1388–93 |year=2006 |pmid=16908728 |doi=10.1001/archneur.63.10.noc60076}}
53. ^{{cite journal |vauthors=Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Pia Amato M |title=Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety |journal= Journal of the Neurological Sciences|volume= 266|issue= 1–2|pages= 25–30|year=2007 |pmid=17870094 |doi=10.1016/j.jns.2007.08.023}}
54. ^{{cite journal |vauthors=Krishnan C, Kaplin AI, Brodsky RA, etal |title=Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis |journal=Arch. Neurol. |volume= 65|issue= 8|pages= 1044–51|date=June 2008 |pmid=18541787 |doi=10.1001/archneurol.65.8.noc80042 |url= |pmc=2574697}}
55. ^{{cite journal | last=Chataway |first=J | year = 2014 | title = Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial | url = | journal = The Lancet | volume = 383 | issue = 9936| pages = 2213–2221 | doi=10.1016/s0140-6736(13)62242-4 | pmid=24655729}}
56. ^Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis [https://finance.yahoo.com/news/opexa-initiates-stage-clinical-study-110500862.html]
57. ^{{cite journal |doi=10.1590/S0004-282X2008000300013 |vauthors=de Araújo EA, de Freitas MR |title=Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years |journal=Arq Neuropsiquiatr |volume=66 |issue=2B |pages=350–3 |date=June 2008 |pmid=18641870 |url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2008000300013&lng=en&nrm=iso&tlng=en}}
58. ^{{cite journal |vauthors=Killestein J, Kalkers NF, Polman CH |title=Glutamate inhibition in MS: the neuroprotective properties of riluzole |journal=J Neurol Sci |volume=233 |issue=1–2 |pages=113–5 |date=June 2005 |pmid=15949499 |doi=10.1016/j.jns.2005.03.011 }}
59. ^{{cite journal |vauthors=Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G |title=A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis |journal=Multiple Sclerosis |volume=14 |issue=8 |pages=1076–83 |year=2008 |pmid=18728058 |doi=10.1177/1352458508095828}}
60. ^{{cite journal | author = Gajofatto A, Turatti M, Benedetti MD | year = 2016 | title = Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives | url = | journal = Expert Rev Neurother | volume = 17| issue = 4| pages = 1–14| doi = 10.1080/14737175.2017.1257385 | pmid = 27813441 }}
61. ^{{cite journal | author = Castro-Borrero Wanda|display-authors=etal| year = 2012 | title = Current and emerging therapies in multiple sclerosis: a systematic review | url = | journal = Therapeutic Advances in Neurological Disorders | volume = 5 | issue = 4| pages = 205–220 | doi = 10.1177/1756285612450936 | pmid = 22783370 | pmc = 3388530 }}
62. ^Statin may slow progressive MS
63. ^{{cite journal | last=Wang |first=Z | year = 2016| title = Nuclear Receptor NR1H3 in Familial Multiple Sclerosis | journal = Neuron | volume = 90 | issue = 5| pages = 948–954 | doi = 10.1016/j.neuron.2016.04.039 | pmid=27253448 | pmc=5092154}}
64. ^First Oral Treatment For Highly Active Relapsing Remitting Multiple Sclerosis Provides New Choice For UK Patients Failing On Injections,  
65. ^{{cite journal | pmid = 11990872 | volume=8 | issue=2 | title=Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects |date=April 2002 |vauthors=Weiner HL, Cohen JA | journal=Mult. Scler. | pages=142–54 | doi=10.1191/1352458502ms790oa}}
{{Multiple sclerosis}}

3 : Autoimmune diseases|Multiple sclerosis|Medical treatments
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/12 8:16:39